BRPI0913235A2 - forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona - Google Patents

forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona

Info

Publication number: BRPI0913235A2
Authority: BR; Brazil
Prior art keywords: dosage form; pharmaceutical dosage; immediate release; indolinone derivative; indolinone
Prior art date: 2008-06-06

Application number

BRPI0913235A

Other languages

English (en)

Inventor

Dirk Trommeshauser

Peter Lach

Peter Stopfer

Roman Messerschmid

Torsten Sokoliess

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-06

Filing date

2009-06-04

Publication date

2016-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913235(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-04 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2016-01-19 Publication of BRPI0913235A2 publication Critical patent/BRPI0913235A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Business, Economics & Management (AREA)
Physics & Mathematics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Entrepreneurship & Innovation (AREA)
Educational Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medical Informatics (AREA)
Surgery (AREA)
Dispersion Chemistry (AREA)
Immunology (AREA)
Pathology (AREA)
Biomedical Technology (AREA)
General Physics & Mathematics (AREA)
Educational Administration (AREA)
Theoretical Computer Science (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BRPI0913235A 2008-06-06 2009-06-04 forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona BRPI0913235A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08157750		2008-06-06
PCT/EP2009/056895 WO2009147220A1 (en)	2008-06-06	2009-06-04	Pharmaceutical dosage form for immediate release of an indolinone derivative

Publications (1)

Publication Number	Publication Date
BRPI0913235A2 true BRPI0913235A2 (pt)	2016-01-19

Family

ID=41017080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913235A BRPI0913235A2 (pt)	2008-06-06	2009-06-04	forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona

Country Status (35)

Country	Link
US (3)	US20110190318A1 (pt)
EP (1)	EP2313087B2 (pt)
JP (2)	JP5583119B2 (pt)
KR (1)	KR20110022586A (pt)
CN (1)	CN102056599A (pt)
AR (1)	AR072060A1 (pt)
AU (1)	AU2009254556B2 (pt)
BR (1)	BRPI0913235A2 (pt)
CA (1)	CA2726648A1 (pt)
CL (1)	CL2010001362A1 (pt)
CO (1)	CO6280468A2 (pt)
CY (1)	CY1121272T1 (pt)
DK (1)	DK2313087T4 (pt)
EA (1)	EA201001857A1 (pt)
EC (1)	ECSP10010717A (pt)
ES (1)	ES2711913T5 (pt)
FI (1)	FI2313087T4 (pt)
HR (1)	HRP20190181T4 (pt)
HU (1)	HUE042524T2 (pt)
IL (1)	IL209055A0 (pt)
LT (1)	LT2313087T (pt)
MA (1)	MA32386B1 (pt)
MX (1)	MX338001B (pt)
PE (1)	PE20100050A1 (pt)
PL (1)	PL2313087T5 (pt)
PT (1)	PT2313087T (pt)
RS (1)	RS58280B2 (pt)
SG (1)	SG191607A1 (pt)
SI (1)	SI2313087T2 (pt)
TR (1)	TR201901579T4 (pt)
TW (1)	TW201002692A (pt)
UA (1)	UA107560C2 (pt)
UY (1)	UY31876A (pt)
WO (1)	WO2009147220A1 (pt)
ZA (1)	ZA201007972B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040077604A1 (en) *	2001-12-19	2004-04-22	Lenard Lichtenberger	Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
ES2669469T3 (es) *	2008-06-06	2018-05-25	Boehringer Ingelheim International Gmbh	Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona
BR112015006363A2 (pt)	2012-09-28	2017-08-08	Boehringer Ingelheim Int	combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
WO2014197415A1 (en)	2013-06-04	2014-12-11	Monosol Llc	Water-soluble film sealing solutions, related methods, and related articles
US20150044288A1 (en)	2013-07-31	2015-02-12	Windward Pharma, Inc.	Aerosol tyrosine kinase inhibitor compounds and uses thereof
AU2016276170B2 (en)	2015-06-06	2021-08-05	Cloudbreak Therapeutics, Llc	Compositions and methods for treating pterygium
WO2017210130A1 (en)	2016-06-02	2017-12-07	Cloudbreak Therapeutics, Llc	Compositions and methods of using nintedanib for improving glaucoma surgery success
WO2018108669A1 (en)	2016-12-12	2018-06-21	Boehringer Ingelheim International Gmbh	Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
EP3600322A1 (en) *	2017-03-28	2020-02-05	Boehringer Ingelheim International GmbH	Nintedanib for use in methods for the treatment of muscular dystrophy
CN111278442B (zh)	2017-10-23	2023-06-06	勃林格殷格翰国际有限公司	用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合
CN112135612B (zh)	2018-03-07	2025-06-17	普利安特治疗公司	氨基酸化合物和使用方法
WO2021198253A1 (en)	2020-04-01	2021-10-07	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation of nintedanib
JP2025525881A (ja)	2022-08-16	2025-08-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	眼内使用するためのニンテダニブの医薬製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3579384D1 (de)	1984-07-24	1990-10-04	Scherer Gmbh R P	Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
DE19603402A1 (de)	1995-02-24	1996-08-29	Basf Ag	Weichgelatinekapseln
US6762180B1 (en)	1999-10-13	2004-07-13	Boehringer Ingelheim Pharma Kg	Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) *	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) *	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20090306101A1 (en)	2005-11-11	2009-12-10	Flavio Solca	Combination treatment of cancer comprising egfr/her2 inhibitors
LT2985025T (lt) *	2008-06-06	2018-04-10	Boehringer Ingelheim International Gmbh	Farmacinis derinys
ES2669469T3 (es) *	2008-06-06	2018-05-25	Boehringer Ingelheim International Gmbh	Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona
EP2387401A1 (en) *	2009-01-14	2011-11-23	Boehringer Ingelheim International GmbH	Method for treating colorectal cancer
US8802384B2 (en) *	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
EP2647375A1 (en) *	2009-05-14	2013-10-09	Boehringer Ingelheim International Gmbh	Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases

2009
- 2009-04-06 UA UAA201100096A patent/UA107560C2/ru unknown
- 2009-06-04 HR HRP20190181TT patent/HRP20190181T4/hr unknown
- 2009-06-04 FI FIEP09757601.1T patent/FI2313087T4/fi active
- 2009-06-04 US US12/995,893 patent/US20110190318A1/en not_active Abandoned
- 2009-06-04 WO PCT/EP2009/056895 patent/WO2009147220A1/en not_active Ceased
- 2009-06-04 HU HUE09757601A patent/HUE042524T2/hu unknown
- 2009-06-04 JP JP2011512134A patent/JP5583119B2/ja active Active
- 2009-06-04 TR TR2019/01579T patent/TR201901579T4/tr unknown
- 2009-06-04 PT PT09757601T patent/PT2313087T/pt unknown
- 2009-06-04 LT LTEP09757601.1T patent/LT2313087T/lt unknown
- 2009-06-04 DK DK09757601.1T patent/DK2313087T4/da active
- 2009-06-04 KR KR1020107027313A patent/KR20110022586A/ko not_active Ceased
- 2009-06-04 EA EA201001857A patent/EA201001857A1/ru unknown
- 2009-06-04 CA CA2726648A patent/CA2726648A1/en not_active Abandoned
- 2009-06-04 MX MX2010013092A patent/MX338001B/es active IP Right Grant
- 2009-06-04 BR BRPI0913235A patent/BRPI0913235A2/pt not_active IP Right Cessation
- 2009-06-04 PE PE2009000780A patent/PE20100050A1/es not_active Application Discontinuation
- 2009-06-04 SI SI200931930T patent/SI2313087T2/sl unknown
- 2009-06-04 ES ES09757601T patent/ES2711913T5/es active Active
- 2009-06-04 PL PL09757601.1T patent/PL2313087T5/pl unknown
- 2009-06-04 RS RS20190128A patent/RS58280B2/sr unknown
- 2009-06-04 AU AU2009254556A patent/AU2009254556B2/en active Active
- 2009-06-04 SG SG2013040332A patent/SG191607A1/en unknown
- 2009-06-04 EP EP09757601.1A patent/EP2313087B2/en active Active
- 2009-06-04 CN CN200980121070XA patent/CN102056599A/zh active Pending
- 2009-06-05 AR ARP090102040A patent/AR072060A1/es unknown
- 2009-06-05 TW TW098118827A patent/TW201002692A/zh unknown
- 2009-06-08 UY UY0001031876A patent/UY31876A/es not_active Application Discontinuation
2010
- 2010-11-01 IL IL209055A patent/IL209055A0/en unknown
- 2010-11-08 ZA ZA2010/07972A patent/ZA201007972B/en unknown
- 2010-12-03 CO CO10152530A patent/CO6280468A2/es not_active Application Discontinuation
- 2010-12-06 MA MA33403A patent/MA32386B1/fr unknown
- 2010-12-06 CL CL2010001362A patent/CL2010001362A1/es unknown
- 2010-12-23 EC EC2010010717A patent/ECSP10010717A/es unknown
2013
- 2013-03-08 US US13/790,334 patent/US20130203773A1/en not_active Abandoned
2014
- 2014-02-10 US US14/176,478 patent/US20140163040A1/en not_active Abandoned
- 2014-02-28 JP JP2014039871A patent/JP5992937B2/ja active Active
2019
- 2019-02-19 CY CY20191100212T patent/CY1121272T1/el unknown

Also Published As

Publication number	Publication date
AU2009254556A1 (en)	2009-12-10
DK2313087T3 (en)	2019-02-18
EA201001857A1 (ru)	2011-06-30
JP2014098045A (ja)	2014-05-29
MX338001B (es)	2016-03-30
RS58280B2 (sr)	2024-02-29
ES2711913T3 (es)	2019-05-08
WO2009147220A1 (en)	2009-12-10
CL2010001362A1 (es)	2011-05-13
ZA201007972B (en)	2011-07-27
PL2313087T5 (pl)	2024-03-04
ECSP10010717A (es)	2011-02-28
JP5992937B2 (ja)	2016-09-14
PT2313087T (pt)	2019-02-15
DK2313087T4 (da)	2024-01-15
MA32386B1 (fr)	2011-06-01
UY31876A (es)	2010-01-29
RS58280B1 (sr)	2019-03-29
PL2313087T3 (pl)	2019-05-31
IL209055A0 (en)	2011-01-31
KR20110022586A (ko)	2011-03-07
AR072060A1 (es)	2010-08-04
TW201002692A (en)	2010-01-16
SI2313087T1 (sl)	2019-03-29
SG191607A1 (en)	2013-07-31
TR201901579T4 (tr)	2019-02-21
JP2011522010A (ja)	2011-07-28
HRP20190181T4 (hr)	2024-07-05
PE20100050A1 (es)	2010-01-29
AU2009254556B2 (en)	2015-08-20
LT2313087T (lt)	2019-02-25
UA107560C2 (uk)	2015-01-26
US20140163040A1 (en)	2014-06-12
EP2313087B1 (en)	2018-11-21
CN102056599A (zh)	2011-05-11
EP2313087B2 (en)	2023-11-22
HRP20190181T1 (hr)	2019-03-22
JP5583119B2 (ja)	2014-09-03
HUE042524T2 (hu)	2019-07-29
CA2726648A1 (en)	2009-12-10
CY1121272T1 (el)	2020-05-29
US20130203773A1 (en)	2013-08-08
MX2010013092A (es)	2011-02-25
FI2313087T4 (fi)	2023-12-28
CO6280468A2 (es)	2011-05-20
ES2711913T5 (es)	2024-06-24
EP2313087A1 (en)	2011-04-27
US20110190318A1 (en)	2011-08-04
SI2313087T2 (sl)	2024-03-29

Publication	Publication Date	Title
BRPI0913235A2 (pt)	2016-01-19	forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
CY2020036I1 (el)	2021-03-12	Δοσολογικο σχημα για εναν αγωνιστη του υποδοχεα s1p
IL283459A (en)	2021-06-30	Novel lipids and compositions for the delivery of therapeutics
DK2345410T3 (da)	2021-02-01	Farmaceutisk sammensætning til modificeret frigivelse
BRPI0913434A2 (pt)	2015-12-01	forma de dosagem farmacêutica em cápsula compreendendo uma formulação de um derivado de indolinona em supensão
BRPI0909780A2 (pt)	2015-08-11	Composições e métodos para liberação de fármaco
BRPI0918971A2 (pt)	2015-12-01	tienopirimidinas para composições farmacêuticas
EP2240022A4 (en)	2012-04-25	PHARMACEUTICAL COMPOSITIONS
EP2373681A4 (en)	2013-11-06	PHARMACEUTICAL COMPOSITIONS
BRPI1008598A2 (pt)	2016-03-15	composição farmacêutica para inalação
DK2391351T3 (da)	2014-12-01	Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
BRPI1007484A2 (pt)	2016-02-16	composição farmacêutica para administração oral
BRPI0809288A2 (pt)	2014-10-14	Formulações farmacêuticas auto-precipitação para a liberação modificada de um princípio ativo
DK2271618T3 (da)	2014-06-16	Farmaceutiske forbindelser
BRPI0918539A2 (pt)	2015-12-08	preparação farmacêutica sólida para administração oral
PT2571488E (pt)	2014-07-25	Composição farmacêutica de ibuprofeno para injeção
EP2432320A4 (en)	2013-03-06	PHARMACEUTICAL QUERCETINE COCKRISTALS
BRPI0919194A2 (pt)	2015-12-15	preparação sólida para administração oral
IT1390848B1 (it)	2011-10-19	Composti farmaceutici
PT2429501T (pt)	2019-01-30	Composições de libertação imediata de fármaco
BRPI0923379A2 (pt)	2015-07-21	Formulação para administração por via transmucosa oral de setronas
BRPI0922623A2 (pt)	2016-09-13	comprimido farmacêutico de liberação controlada
HUE037915T2 (hu)	2018-09-28	Gyógyszerészeti készítmények aktív vegyületek felszabadítására
BRPI0919475A2 (pt)	2015-12-01	composição farmacêutica para administração oral

Legal Events

Date	Code	Title	Description
2018-04-03	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-07-24	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.